General Information
Version
8.5
Revision date
2024-03-08
Product name
Methazolamide
CAS No.
554-57-4
REACH No
is
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H302+H312+H332, H312, H332, H351
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Warning Warning
Hazard statements
H302 + H312 + H332 Harmful if swallowed, in contact with skin or if inhaled. H351 Suspected of causing cancer. Reduced Labeling (<= 125 ml) H351 Suspected of causing cancer. 2.3
Precautionary statements
P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P301 + P312 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. P302 + P352 + P312 IF ON SKIN: Wash with plenty of water.Call a POISON CENTER/ doctor if you feel unwell. P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. Caution: Physiologically highly active, therapeutically usable substance. The substance must be handled with the care required for hazardous materials. SECTION 3: Composition/information on ingredients
